Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study

{ 'indexed': {'date-parts': [[2024, 4, 13]], 'date-time': '2024-04-13T00:36:43Z', 'timestamp': 1712968603316}, 'reference-count': 28, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2024, 4, 12]], 'date-time': '2024-04-12T00:00:00Z', 'timestamp': 1712880000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2024, 4, 12]], 'date-time': '2024-04-12T00:00:00Z', 'timestamp': 1712880000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [{'DOI': '10.13039/100018592', 'name': 'Celltrion', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s40121-024-00971-w', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 12]], 'date-time': '2024-04-12T13:01:45Z', 'timestamp': 1712926905000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A ' 'Propensity Score-Matched Cohort Study', 'prefix': '10.1007', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3618-174X', 'authenticated-orcid': False, 'given': 'Soyoon', 'family': 'Hwang', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3381-1382', 'authenticated-orcid': False, 'given': 'Nan Young', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9845-3563', 'authenticated-orcid': False, 'given': 'Eunkyung', 'family': 'Nam', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4699-8502', 'authenticated-orcid': False, 'given': 'Yu Kyung', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3755-8249', 'authenticated-orcid': False, 'given': 'Shin-Woo', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9405-2121', 'authenticated-orcid': False, 'given': 'Hyun-Ha', 'family': 'Chang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7454-4014', 'authenticated-orcid': False, 'given': 'Yoonjung', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0206-7108', 'authenticated-orcid': False, 'given': 'Sohyun', 'family': 'Bae', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0003-5004-6998', 'authenticated-orcid': False, 'given': 'Juhwan', 'family': 'Jeong', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6450-9787', 'authenticated-orcid': False, 'given': 'Jae-Ho', 'family': 'Shin', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3108-8087', 'authenticated-orcid': False, 'given': 'Guehwan', 'family': 'Jang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5930-5461', 'authenticated-orcid': False, 'given': 'Changhee', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4666-0672', 'authenticated-orcid': False, 'given': 'Ki Tae', 'family': 'Kwon', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 4, 12]]}, 'reference': [ { 'issue': '2', 'key': '971_CR1', 'doi-asserted-by': 'publisher', 'first-page': '87', 'DOI': '10.1016/j.bsheal.2021.02.001', 'volume': '3', 'author': 'P Deb', 'year': '2021', 'unstructured': 'Deb P, Molla MMA, Saif-Ur-Rahman K. An update to monoclonal antibody as ' 'therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87–91.', 'journal-title': 'Biosaf Health'}, { 'issue': '1', 'key': '971_CR2', 'doi-asserted-by': 'publisher', 'first-page': '288', 'DOI': '10.1038/s41467-020-20602-5', 'volume': '12', 'author': 'C Kim', 'year': '2021', 'unstructured': 'Kim C, Ryu D-K, Lee J, et al. A therapeutic neutralizing antibody ' 'targeting receptor binding domain of SARS-CoV-2 spike protein. Nat ' 'Commun. 2021;12(1):288.', 'journal-title': 'Nat Commun'}, { 'issue': '18', 'key': '971_CR3', 'doi-asserted-by': 'publisher', 'first-page': '2133', 'DOI': '10.1007/s40265-021-01626-7', 'volume': '81', 'author': 'YY Syed', 'year': '2021', 'unstructured': 'Syed YY. Regdanvimab: First approval. Drugs. 2021;81(18):2133–7.', 'journal-title': 'Drugs'}, { 'key': '971_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'ofac053', 'DOI': '10.1093/ofid/ofac053', 'volume': '9', 'author': 'A Streinu-Cercel', 'year': '2022', 'unstructured': 'Streinu-Cercel A, Săndulescu O, Preotescu L-L, et al. Efficacy and ' 'safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, ' 'placebo-controlled trial in outpatients with mild-to-moderate ' 'coronavirus disease 2019. Open Forum Infect Dis. 2022;9:ofac053.', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '971_CR5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.envres.2021.112240', 'volume': '206', 'author': 'Y Zhao', 'year': '2022', 'unstructured': 'Zhao Y, Huang J, Zhang L, Chen S, Gao J, Jiao H. The global transmission ' 'of new coronavirus variants. Environ Res. 2022;206: 112240.', 'journal-title': 'Environ Res'}, { 'key': '971_CR6', 'doi-asserted-by': 'publisher', 'first-page': '31', 'DOI': '10.1146/annurev-med-042921-020956', 'volume': '74', 'author': 'JL Jacobs', 'year': '2023', 'unstructured': 'Jacobs JL, Haidar G, Mellors JW. COVID-19: challenges of viral variants. ' 'Ann Rev Med. 2023;74:31–53.', 'journal-title': 'Ann Rev Med'}, { 'issue': '7898', 'key': '971_CR7', 'doi-asserted-by': 'publisher', 'first-page': '671', 'DOI': '10.1038/s41586-021-04389-z', 'volume': '602', 'author': 'D Planas', 'year': '2022', 'unstructured': 'Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 ' 'omicron to antibody neutralization. Nature. 2022;602(7898):671–5.', 'journal-title': 'Nature'}, { 'key': '971_CR8', 'doi-asserted-by': 'publisher', 'first-page': '91', 'DOI': '10.1016/j.bbrc.2021.09.023', 'volume': '578', 'author': 'D-K Ryu', 'year': '2021', 'unstructured': 'Ryu D-K, Kang B, Noh H, et al. The in vitro and in vivo efficacy of ' 'CT-P59 against gamma, delta and its associated variants of SARS-CoV-2. ' 'Biochem Biophys Res Commun. 2021;578:91–6.', 'journal-title': 'Biochem Biophys Res Commun'}, { 'key': '971_CR9', 'doi-asserted-by': 'publisher', 'first-page': '94', 'DOI': '10.1016/j.ijid.2022.12.035', 'volume': '130', 'author': 'YR Jang', 'year': '2023', 'unstructured': 'Jang YR, Oh YJ, Kim JY. Regdanvimab for patients with mild-to-moderate ' 'COVID-19: a retrospective cohort study and subgroup analysis of patients ' 'with the delta variant. Int J Infect Dis. 2023;130:94–100.', 'journal-title': 'Int J Infect Dis'}, { 'issue': '4', 'key': '971_CR10', 'doi-asserted-by': 'publisher', 'first-page': '781', 'DOI': '10.3947/ic.2022.0103', 'volume': '54', 'author': 'YG Kwak', 'year': '2022', 'unstructured': 'Kwak YG, Song JE, Kang J, et al. Use of the monoclonal antibody ' 'regdanvimab to treat patients hospitalized with COVID-19: real-world ' 'data during the delta variant predominance. Infect Chemother. ' '2022;54(4):781.', 'journal-title': 'Infect Chemother'}, { 'key': '971_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1192512', 'DOI': '10.3389/fcimb.2023.1192512', 'volume': '13', 'author': 'H Kim', 'year': '2023', 'unstructured': 'Kim H, Jang YR, Lee JY, et al. Effectiveness of regdanvimab treatment ' 'for SARS-CoV-2 delta variant, which exhibited decreased in vitro ' 'activity: a nationwide real-world multicenter cohort study. Front Cell ' 'Infect Microbiol. 2023;13:1192512.', 'journal-title': 'Front Cell Infect Microbiol'}, { 'issue': '12', 'key': '971_CR12', 'doi-asserted-by': 'publisher', 'first-page': '459', 'DOI': '10.15585/mmwr.mm7112e1', 'volume': '71', 'author': 'MW Tenforde', 'year': '2022', 'unstructured': 'Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA ' 'vaccination in preventing COVID-19-associated invasive mechanical ' 'ventilation and death—United States, March 2021–January 2022. Morb ' 'Mortal Wkly Rep. 2022;71(12):459.', 'journal-title': 'Morb Mortal Wkly Rep'}, { 'issue': '3', 'key': '971_CR13', 'doi-asserted-by': 'publisher', 'first-page': '430', 'DOI': '10.3390/vaccines10030430', 'volume': '10', 'author': 'S Kodera', 'year': '2022', 'unstructured': 'Kodera S, Rashed EA, Hirata A. Estimation of real-world vaccination ' 'effectiveness of mRNA COVID-19 vaccines against delta and omicron ' 'variants in Japan. Vaccines. 2022;10(3):430.', 'journal-title': 'Vaccines'}, { 'key': '971_CR14', 'doi-asserted-by': 'publisher', 'first-page': '327', 'DOI': '10.1016/j.mayocp.2021.12.002', 'volume': '97', 'author': 'JC O’Horo', 'year': '2022', 'unstructured': 'O’Horo JC, Challener DW, Speicher L, et al. Effectiveness of monoclonal ' 'antibodies in preventing severe COVID-19 with emergence of the delta ' 'variant. Mayo Clin Proc. 2022;97:327–32.', 'journal-title': 'Mayo Clin Proc'}, { 'issue': '1', 'key': '971_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'e27', 'DOI': '10.1093/cid/ciac239', 'volume': '75', 'author': 'S Park', 'year': '2022', 'unstructured': 'Park S, Lim SY, Kim JY, et al. Clinical and virological characteristics ' 'of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ' 'B.1.617.2 (delta) variant: a prospective cohort study. Clin Infect Dis. ' '2022;75(1):e27–34.', 'journal-title': 'Clin Infect Dis'}, { 'key': '971_CR16', 'unstructured': 'National Institutes of Health. National Institutes of Health COVID-19 ' 'treatment guidelines. Therapeutic management of nonhospitalized adults ' 'with COVID. ' 'https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/. ' 'Accessed 2 Nov 2023.'}, { 'issue': '2', 'key': '971_CR17', 'doi-asserted-by': 'publisher', 'first-page': '258', 'DOI': '10.3947/ic.2022.0011', 'volume': '54', 'author': 'CM Lee', 'year': '2022', 'unstructured': 'Lee CM, Park S-W, Lee E. Early oxygen requirement in patients with ' 'wild-to-moderate COVID-19 who received regdanvimab after delta-variant ' 'outbreak. Infect Chemother. 2022;54(2):258.', 'journal-title': 'Infect Chemother'}, { 'issue': '6', 'key': '971_CR18', 'doi-asserted-by': 'publisher', 'first-page': '971', 'DOI': '10.1002/oby.23172', 'volume': '29', 'author': 'BG Tchang', 'year': '2021', 'unstructured': 'Tchang BG, Askin G, Sahagun A, et al. The independent risk of obesity ' 'and diabetes and their interaction in COVID-19: a retrospective cohort ' 'study. Obesity. 2021;29(6):971–5.', 'journal-title': 'Obesity'}, { 'key': '971_CR19', 'doi-asserted-by': 'publisher', 'first-page': '15', 'DOI': '10.1016/j.ejim.2021.12.024', 'volume': '98', 'author': 'M Holland', 'year': '2022', 'unstructured': 'Holland M, Kellett J. A systematic review of the discrimination and ' 'absolute mortality predicted by the National Early Warning Scores ' 'according to different cut-off values and prediction windows. Eur J ' 'Intern Med. 2022;98:15–26.', 'journal-title': 'Eur J Intern Med'}, { 'issue': '6', 'key': '971_CR20', 'doi-asserted-by': 'publisher', 'first-page': '433', 'DOI': '10.1097/MEJ.0000000000000589', 'volume': '26', 'author': 'DJ Silcock', 'year': '2019', 'unstructured': 'Silcock DJ, Corfield AR, Staines H, Rooney KD. Superior performance of ' 'National Early Warning Score compared with quick Sepsis-related Organ ' 'Failure Assessment Score in predicting adverse outcomes: a retrospective ' 'observational study of patients in the prehospital setting. Eur J Emerg ' 'Med. 2019;26(6):433–9.', 'journal-title': 'Eur J Emerg Med'}, { 'issue': '83–85', 'key': '971_CR21', 'first-page': '7', 'volume': '5', 'author': 'S Alexandar', 'year': '2021', 'unstructured': 'Alexandar S, Ravisankar M, Kumar RS, Jakkan K. A comprehensive review on ' 'Covid-19 delta variant. Int J Pharmacol Clin Res (IJPCR). ' '2021;5(83–85):7.', 'journal-title': 'Int J Pharmacol Clin Res (IJPCR)'}, { 'issue': '1', 'key': '971_CR22', 'doi-asserted-by': 'publisher', 'first-page': '35', 'DOI': '10.1016/S1473-3099(21)00475-8', 'volume': '22', 'author': 'KA Twohig', 'year': '2022', 'unstructured': 'Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency ' 'care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with ' 'alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect ' 'Dis. 2022;22(1):35–42.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '971_CR23', 'doi-asserted-by': 'crossref', 'unstructured': 'Khedar RS, Mittal K, Ambaliya HC, et al. Greater Covid-19 severity and ' 'mortality in hospitalized patients in second (delta variant) wave ' 'compared to the first: single centre prospective study in India. ' 'medRxiv. 2021:2021.09. 03.21263091.', 'DOI': '10.1101/2021.09.03.21263091'}, { 'issue': '1', 'key': '971_CR24', 'doi-asserted-by': 'publisher', 'first-page': '18918', 'DOI': '10.1038/s41598-022-23312-8', 'volume': '12', 'author': 'A Zali', 'year': '2022', 'unstructured': 'Zali A, Khodadoost M, Gholamzadeh S, et al. Mortality among hospitalized ' 'COVID-19 patients during surges of SARS-CoV-2 alpha (B. 1.1. 7) and ' 'delta (B. 1. 617. 2) variants. Sci Rep. 2022;12(1):18918.', 'journal-title': 'Sci Rep'}, { 'issue': '4', 'key': '971_CR25', 'doi-asserted-by': 'publisher', 'first-page': '628', 'DOI': '10.3390/v13040628', 'volume': '13', 'author': 'AC Hurt', 'year': '2021', 'unstructured': 'Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. ' 'Viruses. 2021;13(4):628.', 'journal-title': 'Viruses'}, { 'issue': '1', 'key': '971_CR26', 'doi-asserted-by': 'publisher', 'first-page': '4683', 'DOI': '10.1038/s41598-022-08559-5', 'volume': '12', 'author': 'F Touret', 'year': '2022', 'unstructured': 'Touret F, Baronti C, Bouzidi HS, de Lamballerie X. In vitro evaluation ' 'of therapeutic antibodies against a SARS-CoV-2 Omicron B. 1.1. 529 529 ' 'isolate. Sci Rep. 2022;12(1):4683.', 'journal-title': 'Sci Rep'}, { 'issue': '1', 'key': '971_CR27', 'doi-asserted-by': 'publisher', 'first-page': '44', 'DOI': '10.1016/j.chom.2020.11.007', 'volume': '29', 'author': 'AJ Greaney', 'year': '2021', 'unstructured': 'Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to ' 'the SARS-CoV-2 spike receptor-binding domain that escape antibody ' 'recognition. Cell Host Microbe. 2021;29(1):44-57.e9.', 'journal-title': 'Cell Host Microbe'}, { 'key': '971_CR28', 'doi-asserted-by': 'crossref', 'unstructured': 'Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: evasion of ' 'potent humoral responses and resistance to clinical immunotherapeutics ' 'relative to viral variants of concern. medRxiv: 2021-12 (2021)', 'DOI': '10.1101/2021.12.14.21267772'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-024-00971-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-024-00971-w/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-024-00971-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 12]], 'date-time': '2024-04-12T13:31:27Z', 'timestamp': 1712928687000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-024-00971-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 12]]}, 'references-count': 28, 'alternative-id': ['971'], 'URL': 'http://dx.doi.org/10.1007/s40121-024-00971-w', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2024, 4, 12]]}, 'assertion': [ { 'value': '15 February 2024', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 March 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 April 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Soyoon Hwang, Nan Young Lee, Eunkyung Nam, Yu Kyung Kim, Shin-Woo Kim, Hyun-Ha ' 'Chang, Yoonjung Kim, Sohyun Bae, Juhwan Jeong, Jae-Ho Shin, Guehwan Jang, ' 'Changhee Lee, and Ki Tae Kwon declare no conflicts of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest'}}, { 'value': 'This study was approved by the Daegu Joint Institutional Review Board, and the ' 'requirement for official written informed consent was waived (DGIRB ' '2021-10-002), given the retrospective nature of the study (using EMR and ' 'residual samples).', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethical Approval and Informed Consent'}}]}